nodes	percent_of_prediction	percent_of_DWPC	metapath
Canagliflozin—SLC5A2—type 2 diabetes mellitus	0.353	0.763	CbGaD
Canagliflozin—ABCC2—type 2 diabetes mellitus	0.06	0.13	CbGaD
Canagliflozin—UGT1A9—Nateglinide—type 2 diabetes mellitus	0.0483	0.144	CbGbCtD
Canagliflozin—ORM1—Nateglinide—type 2 diabetes mellitus	0.0356	0.106	CbGbCtD
Canagliflozin—CYP3A4—type 2 diabetes mellitus	0.0265	0.0574	CbGaD
Canagliflozin—ALB—Gliclazide—type 2 diabetes mellitus	0.0232	0.0694	CbGbCtD
Canagliflozin—ALB—type 2 diabetes mellitus	0.0231	0.05	CbGaD
Canagliflozin—ALB—Repaglinide—type 2 diabetes mellitus	0.0218	0.0653	CbGbCtD
Canagliflozin—ALB—Rosiglitazone—type 2 diabetes mellitus	0.0182	0.0545	CbGbCtD
Canagliflozin—ABCC2—Glyburide—type 2 diabetes mellitus	0.0162	0.0485	CbGbCtD
Canagliflozin—ALB—Valsartan—type 2 diabetes mellitus	0.0161	0.0481	CbGbCtD
Canagliflozin—ABCB1—Linagliptin—type 2 diabetes mellitus	0.016	0.0479	CbGbCtD
Canagliflozin—ALB—Nateglinide—type 2 diabetes mellitus	0.015	0.0447	CbGbCtD
Canagliflozin—ABCB1—Sitagliptin—type 2 diabetes mellitus	0.0143	0.0427	CbGbCtD
Canagliflozin—ABCB1—Chlorpropamide—type 2 diabetes mellitus	0.0103	0.0309	CbGbCtD
Canagliflozin—ALB—Glyburide—type 2 diabetes mellitus	0.0101	0.0302	CbGbCtD
Canagliflozin—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.00961	0.0287	CbGbCtD
Canagliflozin—ALB—Losartan—type 2 diabetes mellitus	0.00925	0.0276	CbGbCtD
Canagliflozin—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.00856	0.0256	CbGbCtD
Canagliflozin—CYP3A4—Glipizide—type 2 diabetes mellitus	0.00783	0.0234	CbGbCtD
Canagliflozin—ABCB1—Bromocriptine—type 2 diabetes mellitus	0.0071	0.0212	CbGbCtD
Canagliflozin—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.00685	0.0205	CbGbCtD
Canagliflozin—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.00619	0.0185	CbGbCtD
Canagliflozin—ABCB1—Glyburide—type 2 diabetes mellitus	0.00529	0.0158	CbGbCtD
Canagliflozin—ABCB1—Losartan—type 2 diabetes mellitus	0.00484	0.0145	CbGbCtD
Canagliflozin—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.00469	0.014	CbGbCtD
Canagliflozin—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.0045	0.0134	CbGbCtD
Canagliflozin—CYP3A4—Orlistat—type 2 diabetes mellitus	0.0045	0.0134	CbGbCtD
Canagliflozin—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.00425	0.0127	CbGbCtD
Canagliflozin—CYP3A4—Glyburide—type 2 diabetes mellitus	0.00317	0.00947	CbGbCtD
Canagliflozin—Dapagliflozin—SLC5A4—type 2 diabetes mellitus	0.00308	0.594	CrCbGaD
Canagliflozin—CYP3A4—Losartan—type 2 diabetes mellitus	0.0029	0.00866	CbGbCtD
Canagliflozin—SLC5A2—nephron tubule—type 2 diabetes mellitus	0.00183	0.121	CbGeAlD
Canagliflozin—Dapagliflozin—SLC5A2—type 2 diabetes mellitus	0.00177	0.341	CrCbGaD
Canagliflozin—SLC5A2—kidney—type 2 diabetes mellitus	0.00161	0.107	CbGeAlD
Canagliflozin—SLC5A2—cortex of kidney—type 2 diabetes mellitus	0.00157	0.104	CbGeAlD
Canagliflozin—SLC5A1—nephron tubule—type 2 diabetes mellitus	0.00139	0.092	CbGeAlD
Canagliflozin—SLC5A1—cardiovascular system—type 2 diabetes mellitus	0.00125	0.0827	CbGeAlD
Canagliflozin—SLC5A1—kidney—type 2 diabetes mellitus	0.00122	0.0809	CbGeAlD
Canagliflozin—UGT2B4—cardiovascular system—type 2 diabetes mellitus	0.00115	0.0762	CbGeAlD
Canagliflozin—UGT1A9—kidney—type 2 diabetes mellitus	0.000769	0.0509	CbGeAlD
Canagliflozin—UGT2B4—liver—type 2 diabetes mellitus	0.000711	0.0471	CbGeAlD
Canagliflozin—UGT1A9—liver—type 2 diabetes mellitus	0.000486	0.0322	CbGeAlD
Canagliflozin—ABCC2—nephron tubule—type 2 diabetes mellitus	0.000378	0.025	CbGeAlD
Canagliflozin—ABCC2—kidney—type 2 diabetes mellitus	0.000332	0.022	CbGeAlD
Canagliflozin—ABCC2—cortex of kidney—type 2 diabetes mellitus	0.000324	0.0214	CbGeAlD
Canagliflozin—ORM1—liver—type 2 diabetes mellitus	0.000256	0.0169	CbGeAlD
Canagliflozin—ALB—liver—type 2 diabetes mellitus	0.000224	0.0148	CbGeAlD
Canagliflozin—ABCC2—liver—type 2 diabetes mellitus	0.00021	0.0139	CbGeAlD
Canagliflozin—Dapagliflozin—CYP1A2—type 2 diabetes mellitus	0.000201	0.0388	CrCbGaD
Canagliflozin—ABCB1—islet of Langerhans—type 2 diabetes mellitus	0.000169	0.0112	CbGeAlD
Canagliflozin—CYP3A4—kidney—type 2 diabetes mellitus	0.000169	0.0112	CbGeAlD
Canagliflozin—ABCB1—retina—type 2 diabetes mellitus	0.000144	0.00956	CbGeAlD
Canagliflozin—Shock—Bromocriptine—type 2 diabetes mellitus	0.00014	0.00146	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Pioglitazone—type 2 diabetes mellitus	0.00014	0.00146	CcSEcCtD
Canagliflozin—Fatigue—Pioglitazone—type 2 diabetes mellitus	0.000139	0.00145	CcSEcCtD
Canagliflozin—Nervous system disorder—Bromocriptine—type 2 diabetes mellitus	0.000139	0.00145	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Losartan—type 2 diabetes mellitus	0.000139	0.00145	CcSEcCtD
Canagliflozin—Asthenia—Rosiglitazone—type 2 diabetes mellitus	0.000138	0.00144	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Ramipril—type 2 diabetes mellitus	0.000138	0.00144	CcSEcCtD
Canagliflozin—Skin disorder—Bromocriptine—type 2 diabetes mellitus	0.000138	0.00144	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Glipizide—type 2 diabetes mellitus	0.000138	0.00144	CcSEcCtD
Canagliflozin—Convulsion—Glyburide—type 2 diabetes mellitus	0.000138	0.00144	CcSEcCtD
Canagliflozin—Angiopathy—Valsartan—type 2 diabetes mellitus	0.000137	0.00143	CcSEcCtD
Canagliflozin—Breast disorder—Ramipril—type 2 diabetes mellitus	0.000137	0.00143	CcSEcCtD
Canagliflozin—Pruritus—Rosiglitazone—type 2 diabetes mellitus	0.000136	0.00142	CcSEcCtD
Canagliflozin—ABCB1—nephron tubule—type 2 diabetes mellitus	0.000136	0.00901	CbGeAlD
Canagliflozin—Gastrointestinal disorder—Glimepiride—type 2 diabetes mellitus	0.000136	0.00142	CcSEcCtD
Canagliflozin—Fatigue—Glimepiride—type 2 diabetes mellitus	0.000136	0.00142	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Sitagliptin—type 2 diabetes mellitus	0.000135	0.00141	CcSEcCtD
Canagliflozin—Fatigue—Sitagliptin—type 2 diabetes mellitus	0.000135	0.00141	CcSEcCtD
Canagliflozin—Constipation—Sitagliptin—type 2 diabetes mellitus	0.000134	0.0014	CcSEcCtD
Canagliflozin—Urticaria—Glipizide—type 2 diabetes mellitus	0.000134	0.0014	CcSEcCtD
Canagliflozin—Abdominal pain—Glipizide—type 2 diabetes mellitus	0.000133	0.00139	CcSEcCtD
Canagliflozin—Dapagliflozin—CYP3A4—type 2 diabetes mellitus	0.000133	0.0257	CrCbGaD
Canagliflozin—Hypotension—Bromocriptine—type 2 diabetes mellitus	0.000133	0.00139	CcSEcCtD
Canagliflozin—Urinary tract infection—Losartan—type 2 diabetes mellitus	0.000132	0.00138	CcSEcCtD
Canagliflozin—Malnutrition—Valsartan—type 2 diabetes mellitus	0.000131	0.00137	CcSEcCtD
Canagliflozin—Angioedema—Gliclazide—type 2 diabetes mellitus	0.000131	0.00136	CcSEcCtD
Canagliflozin—Malnutrition—Orlistat—type 2 diabetes mellitus	0.00013	0.00135	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Glimepiride—type 2 diabetes mellitus	0.000129	0.00134	CcSEcCtD
Canagliflozin—Rash—Repaglinide—type 2 diabetes mellitus	0.000129	0.00134	CcSEcCtD
Canagliflozin—Dermatitis—Repaglinide—type 2 diabetes mellitus	0.000128	0.00134	CcSEcCtD
Canagliflozin—Urticaria—Pioglitazone—type 2 diabetes mellitus	0.000128	0.00134	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Sitagliptin—type 2 diabetes mellitus	0.000128	0.00134	CcSEcCtD
Canagliflozin—Pancreatitis—Ramipril—type 2 diabetes mellitus	0.000128	0.00134	CcSEcCtD
Canagliflozin—Urinary tract disorder—Irbesartan—type 2 diabetes mellitus	0.000128	0.00134	CcSEcCtD
Canagliflozin—Shock—Glyburide—type 2 diabetes mellitus	0.000128	0.00133	CcSEcCtD
Canagliflozin—Dizziness—Rosiglitazone—type 2 diabetes mellitus	0.000127	0.00133	CcSEcCtD
Canagliflozin—Nervous system disorder—Glyburide—type 2 diabetes mellitus	0.000127	0.00133	CcSEcCtD
Canagliflozin—Urethral disorder—Irbesartan—type 2 diabetes mellitus	0.000127	0.00133	CcSEcCtD
Canagliflozin—Loss of consciousness—Gliclazide—type 2 diabetes mellitus	0.000126	0.00131	CcSEcCtD
Canagliflozin—Urticaria—Glimepiride—type 2 diabetes mellitus	0.000125	0.00131	CcSEcCtD
Canagliflozin—Urticaria—Sitagliptin—type 2 diabetes mellitus	0.000125	0.0013	CcSEcCtD
Canagliflozin—Angiopathy—Metformin—type 2 diabetes mellitus	0.000125	0.0013	CcSEcCtD
Canagliflozin—Abdominal pain—Glimepiride—type 2 diabetes mellitus	0.000124	0.0013	CcSEcCtD
Canagliflozin—Hypersensitivity—Glipizide—type 2 diabetes mellitus	0.000124	0.0013	CcSEcCtD
Canagliflozin—Abdominal pain—Sitagliptin—type 2 diabetes mellitus	0.000124	0.0013	CcSEcCtD
Canagliflozin—Convulsion—Gliclazide—type 2 diabetes mellitus	0.000124	0.00129	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Bromocriptine—type 2 diabetes mellitus	0.000123	0.00128	CcSEcCtD
Canagliflozin—Fatigue—Bromocriptine—type 2 diabetes mellitus	0.000122	0.00128	CcSEcCtD
Canagliflozin—ABCB1—cardiovascular system—type 2 diabetes mellitus	0.000122	0.00809	CbGeAlD
Canagliflozin—Rash—Rosiglitazone—type 2 diabetes mellitus	0.000122	0.00127	CcSEcCtD
Canagliflozin—Constipation—Bromocriptine—type 2 diabetes mellitus	0.000121	0.00127	CcSEcCtD
Canagliflozin—Dermatitis—Rosiglitazone—type 2 diabetes mellitus	0.000121	0.00127	CcSEcCtD
Canagliflozin—Hypotension—Glyburide—type 2 diabetes mellitus	0.000121	0.00127	CcSEcCtD
Canagliflozin—Nausea—Repaglinide—type 2 diabetes mellitus	0.000121	0.00126	CcSEcCtD
Canagliflozin—Asthenia—Glipizide—type 2 diabetes mellitus	0.000121	0.00126	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Gliclazide—type 2 diabetes mellitus	0.000121	0.00126	CcSEcCtD
Canagliflozin—Angioedema—Valsartan—type 2 diabetes mellitus	0.00012	0.00125	CcSEcCtD
Canagliflozin—ABCB1—kidney—type 2 diabetes mellitus	0.00012	0.00792	CbGeAlD
Canagliflozin—Malnutrition—Metformin—type 2 diabetes mellitus	0.00012	0.00125	CcSEcCtD
Canagliflozin—Erythema—Metformin—type 2 diabetes mellitus	0.00012	0.00125	CcSEcCtD
Canagliflozin—Pruritus—Glipizide—type 2 diabetes mellitus	0.000119	0.00125	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Ramipril—type 2 diabetes mellitus	0.000119	0.00124	CcSEcCtD
Canagliflozin—Hypersensitivity—Pioglitazone—type 2 diabetes mellitus	0.000119	0.00124	CcSEcCtD
Canagliflozin—Dry mouth—Gliclazide—type 2 diabetes mellitus	0.000119	0.00124	CcSEcCtD
Canagliflozin—ABCB1—pancreas—type 2 diabetes mellitus	0.000119	0.00786	CbGeAlD
Canagliflozin—Angioedema—Orlistat—type 2 diabetes mellitus	0.000118	0.00124	CcSEcCtD
Canagliflozin—Syncope—Valsartan—type 2 diabetes mellitus	0.000118	0.00123	CcSEcCtD
Canagliflozin—Angiopathy—Irbesartan—type 2 diabetes mellitus	0.000118	0.00123	CcSEcCtD
Canagliflozin—ABCB1—cortex of kidney—type 2 diabetes mellitus	0.000116	0.00771	CbGeAlD
Canagliflozin—Gastrointestinal pain—Bromocriptine—type 2 diabetes mellitus	0.000116	0.00121	CcSEcCtD
Canagliflozin—Hypersensitivity—Glimepiride—type 2 diabetes mellitus	0.000116	0.00121	CcSEcCtD
Canagliflozin—Asthenia—Pioglitazone—type 2 diabetes mellitus	0.000116	0.00121	CcSEcCtD
Canagliflozin—Infection—Gliclazide—type 2 diabetes mellitus	0.000116	0.00121	CcSEcCtD
Canagliflozin—Hypersensitivity—Sitagliptin—type 2 diabetes mellitus	0.000116	0.00121	CcSEcCtD
Canagliflozin—Loss of consciousness—Valsartan—type 2 diabetes mellitus	0.000115	0.0012	CcSEcCtD
Canagliflozin—Nausea—Rosiglitazone—type 2 diabetes mellitus	0.000114	0.0012	CcSEcCtD
Canagliflozin—Nervous system disorder—Gliclazide—type 2 diabetes mellitus	0.000114	0.00119	CcSEcCtD
Canagliflozin—Skin disorder—Gliclazide—type 2 diabetes mellitus	0.000113	0.00118	CcSEcCtD
Canagliflozin—Urinary tract infection—Ramipril—type 2 diabetes mellitus	0.000113	0.00118	CcSEcCtD
Canagliflozin—Asthenia—Glimepiride—type 2 diabetes mellitus	0.000113	0.00118	CcSEcCtD
Canagliflozin—Urticaria—Bromocriptine—type 2 diabetes mellitus	0.000113	0.00118	CcSEcCtD
Canagliflozin—Erythema—Irbesartan—type 2 diabetes mellitus	0.000113	0.00118	CcSEcCtD
Canagliflozin—Malnutrition—Irbesartan—type 2 diabetes mellitus	0.000113	0.00118	CcSEcCtD
Canagliflozin—Asthenia—Sitagliptin—type 2 diabetes mellitus	0.000113	0.00118	CcSEcCtD
Canagliflozin—Convulsion—Orlistat—type 2 diabetes mellitus	0.000112	0.00117	CcSEcCtD
Canagliflozin—Abdominal pain—Bromocriptine—type 2 diabetes mellitus	0.000112	0.00117	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Glyburide—type 2 diabetes mellitus	0.000112	0.00117	CcSEcCtD
Canagliflozin—Dizziness—Glipizide—type 2 diabetes mellitus	0.000112	0.00116	CcSEcCtD
Canagliflozin—Pruritus—Glimepiride—type 2 diabetes mellitus	0.000111	0.00116	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Valsartan—type 2 diabetes mellitus	0.000111	0.00116	CcSEcCtD
Canagliflozin—Angiopathy—Losartan—type 2 diabetes mellitus	0.000111	0.00115	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Orlistat—type 2 diabetes mellitus	0.00011	0.00114	CcSEcCtD
Canagliflozin—Dry mouth—Valsartan—type 2 diabetes mellitus	0.000109	0.00114	CcSEcCtD
Canagliflozin—Hypotension—Gliclazide—type 2 diabetes mellitus	0.000109	0.00114	CcSEcCtD
Canagliflozin—Dry mouth—Orlistat—type 2 diabetes mellitus	0.000108	0.00113	CcSEcCtD
Canagliflozin—ABCB1—adipose tissue—type 2 diabetes mellitus	0.000108	0.00713	CbGeAlD
Canagliflozin—Syncope—Metformin—type 2 diabetes mellitus	0.000107	0.00112	CcSEcCtD
Canagliflozin—Dizziness—Pioglitazone—type 2 diabetes mellitus	0.000107	0.00112	CcSEcCtD
Canagliflozin—CYP3A4—liver—type 2 diabetes mellitus	0.000107	0.00707	CbGeAlD
Canagliflozin—Infection—Valsartan—type 2 diabetes mellitus	0.000106	0.00111	CcSEcCtD
Canagliflozin—Rash—Glipizide—type 2 diabetes mellitus	0.000106	0.00111	CcSEcCtD
Canagliflozin—Dermatitis—Glipizide—type 2 diabetes mellitus	0.000106	0.00111	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Glyburide—type 2 diabetes mellitus	0.000106	0.00111	CcSEcCtD
Canagliflozin—Erythema—Losartan—type 2 diabetes mellitus	0.000106	0.00111	CcSEcCtD
Canagliflozin—Shock—Valsartan—type 2 diabetes mellitus	0.000105	0.0011	CcSEcCtD
Canagliflozin—Infection—Orlistat—type 2 diabetes mellitus	0.000105	0.0011	CcSEcCtD
Canagliflozin—Loss of consciousness—Metformin—type 2 diabetes mellitus	0.000105	0.0011	CcSEcCtD
Canagliflozin—Nervous system disorder—Valsartan—type 2 diabetes mellitus	0.000105	0.0011	CcSEcCtD
Canagliflozin—Dizziness—Glimepiride—type 2 diabetes mellitus	0.000104	0.00109	CcSEcCtD
Canagliflozin—Skin disorder—Valsartan—type 2 diabetes mellitus	0.000104	0.00109	CcSEcCtD
Canagliflozin—Nervous system disorder—Orlistat—type 2 diabetes mellitus	0.000104	0.00108	CcSEcCtD
Canagliflozin—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.000104	0.00108	CcSEcCtD
Canagliflozin—Urticaria—Glyburide—type 2 diabetes mellitus	0.000103	0.00108	CcSEcCtD
Canagliflozin—Angioedema—Irbesartan—type 2 diabetes mellitus	0.000103	0.00108	CcSEcCtD
Canagliflozin—Skin disorder—Orlistat—type 2 diabetes mellitus	0.000103	0.00107	CcSEcCtD
Canagliflozin—Abdominal pain—Glyburide—type 2 diabetes mellitus	0.000103	0.00107	CcSEcCtD
Canagliflozin—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.000102	0.00106	CcSEcCtD
Canagliflozin—Syncope—Irbesartan—type 2 diabetes mellitus	0.000101	0.00106	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	0.000101	0.00105	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	0.000101	0.00105	CcSEcCtD
Canagliflozin—Fatigue—Gliclazide—type 2 diabetes mellitus	0.000101	0.00105	CcSEcCtD
Canagliflozin—Nausea—Glipizide—type 2 diabetes mellitus	0.0001	0.00105	CcSEcCtD
Canagliflozin—Hypotension—Valsartan—type 2 diabetes mellitus	0.0001	0.00104	CcSEcCtD
Canagliflozin—Constipation—Gliclazide—type 2 diabetes mellitus	9.97e-05	0.00104	CcSEcCtD
Canagliflozin—Rash—Glimepiride—type 2 diabetes mellitus	9.93e-05	0.00104	CcSEcCtD
Canagliflozin—Dermatitis—Glimepiride—type 2 diabetes mellitus	9.92e-05	0.00104	CcSEcCtD
Canagliflozin—Loss of consciousness—Irbesartan—type 2 diabetes mellitus	9.91e-05	0.00103	CcSEcCtD
Canagliflozin—Rash—Sitagliptin—type 2 diabetes mellitus	9.89e-05	0.00103	CcSEcCtD
Canagliflozin—Dermatitis—Sitagliptin—type 2 diabetes mellitus	9.89e-05	0.00103	CcSEcCtD
Canagliflozin—Angioedema—Losartan—type 2 diabetes mellitus	9.7e-05	0.00101	CcSEcCtD
Canagliflozin—Infection—Metformin—type 2 diabetes mellitus	9.69e-05	0.00101	CcSEcCtD
Canagliflozin—Shock—Metformin—type 2 diabetes mellitus	9.6e-05	0.001	CcSEcCtD
Canagliflozin—Hypersensitivity—Glyburide—type 2 diabetes mellitus	9.57e-05	0.000999	CcSEcCtD
Canagliflozin—Nervous system disorder—Metformin—type 2 diabetes mellitus	9.57e-05	0.000999	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	9.54e-05	0.000996	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	9.53e-05	0.000995	CcSEcCtD
Canagliflozin—Syncope—Losartan—type 2 diabetes mellitus	9.52e-05	0.000994	CcSEcCtD
Canagliflozin—Skin disorder—Metformin—type 2 diabetes mellitus	9.47e-05	0.000989	CcSEcCtD
Canagliflozin—Dizziness—Bromocriptine—type 2 diabetes mellitus	9.39e-05	0.00098	CcSEcCtD
Canagliflozin—Dry mouth—Irbesartan—type 2 diabetes mellitus	9.39e-05	0.00098	CcSEcCtD
Canagliflozin—Nausea—Glimepiride—type 2 diabetes mellitus	9.35e-05	0.000976	CcSEcCtD
Canagliflozin—Loss of consciousness—Losartan—type 2 diabetes mellitus	9.33e-05	0.000974	CcSEcCtD
Canagliflozin—Nausea—Sitagliptin—type 2 diabetes mellitus	9.32e-05	0.000973	CcSEcCtD
Canagliflozin—Asthenia—Glyburide—type 2 diabetes mellitus	9.32e-05	0.000972	CcSEcCtD
Canagliflozin—Urticaria—Gliclazide—type 2 diabetes mellitus	9.26e-05	0.000967	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	9.25e-05	0.000965	CcSEcCtD
Canagliflozin—Fatigue—Valsartan—type 2 diabetes mellitus	9.23e-05	0.000964	CcSEcCtD
Canagliflozin—Abdominal pain—Gliclazide—type 2 diabetes mellitus	9.22e-05	0.000962	CcSEcCtD
Canagliflozin—Pruritus—Glyburide—type 2 diabetes mellitus	9.19e-05	0.000959	CcSEcCtD
Canagliflozin—Constipation—Valsartan—type 2 diabetes mellitus	9.16e-05	0.000956	CcSEcCtD
Canagliflozin—Infection—Irbesartan—type 2 diabetes mellitus	9.14e-05	0.000955	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	9.14e-05	0.000954	CcSEcCtD
Canagliflozin—Fatigue—Orlistat—type 2 diabetes mellitus	9.12e-05	0.000953	CcSEcCtD
Canagliflozin—Hypotension—Metformin—type 2 diabetes mellitus	9.11e-05	0.000951	CcSEcCtD
Canagliflozin—Erythema—Ramipril—type 2 diabetes mellitus	9.1e-05	0.00095	CcSEcCtD
Canagliflozin—Malnutrition—Ramipril—type 2 diabetes mellitus	9.1e-05	0.00095	CcSEcCtD
Canagliflozin—Shock—Irbesartan—type 2 diabetes mellitus	9.06e-05	0.000945	CcSEcCtD
Canagliflozin—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	9.03e-05	0.000942	CcSEcCtD
Canagliflozin—Rash—Bromocriptine—type 2 diabetes mellitus	8.95e-05	0.000935	CcSEcCtD
Canagliflozin—Dermatitis—Bromocriptine—type 2 diabetes mellitus	8.95e-05	0.000934	CcSEcCtD
Canagliflozin—Skin disorder—Irbesartan—type 2 diabetes mellitus	8.94e-05	0.000933	CcSEcCtD
Canagliflozin—Dry mouth—Losartan—type 2 diabetes mellitus	8.84e-05	0.000923	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	8.76e-05	0.000914	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	8.65e-05	0.000904	CcSEcCtD
Canagliflozin—Infection—Losartan—type 2 diabetes mellitus	8.61e-05	0.000898	CcSEcCtD
Canagliflozin—Hypotension—Irbesartan—type 2 diabetes mellitus	8.6e-05	0.000898	CcSEcCtD
Canagliflozin—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	8.59e-05	0.000897	CcSEcCtD
Canagliflozin—Shock—Losartan—type 2 diabetes mellitus	8.52e-05	0.00089	CcSEcCtD
Canagliflozin—Urticaria—Valsartan—type 2 diabetes mellitus	8.51e-05	0.000888	CcSEcCtD
Canagliflozin—Nervous system disorder—Losartan—type 2 diabetes mellitus	8.5e-05	0.000887	CcSEcCtD
Canagliflozin—Abdominal pain—Valsartan—type 2 diabetes mellitus	8.47e-05	0.000884	CcSEcCtD
Canagliflozin—Nausea—Bromocriptine—type 2 diabetes mellitus	8.44e-05	0.000881	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	8.42e-05	0.000879	CcSEcCtD
Canagliflozin—Fatigue—Metformin—type 2 diabetes mellitus	8.41e-05	0.000878	CcSEcCtD
Canagliflozin—Urticaria—Orlistat—type 2 diabetes mellitus	8.41e-05	0.000878	CcSEcCtD
Canagliflozin—Abdominal pain—Orlistat—type 2 diabetes mellitus	8.37e-05	0.000873	CcSEcCtD
Canagliflozin—Asthenia—Gliclazide—type 2 diabetes mellitus	8.36e-05	0.000873	CcSEcCtD
Canagliflozin—Constipation—Metformin—type 2 diabetes mellitus	8.34e-05	0.000871	CcSEcCtD
Canagliflozin—Angioedema—Ramipril—type 2 diabetes mellitus	8.32e-05	0.000868	CcSEcCtD
Canagliflozin—Pruritus—Gliclazide—type 2 diabetes mellitus	8.25e-05	0.000861	CcSEcCtD
Canagliflozin—Rash—Glyburide—type 2 diabetes mellitus	8.19e-05	0.000855	CcSEcCtD
Canagliflozin—Dermatitis—Glyburide—type 2 diabetes mellitus	8.18e-05	0.000854	CcSEcCtD
Canagliflozin—Syncope—Ramipril—type 2 diabetes mellitus	8.16e-05	0.000852	CcSEcCtD
Canagliflozin—Hypotension—Losartan—type 2 diabetes mellitus	8.09e-05	0.000845	CcSEcCtD
Canagliflozin—Loss of consciousness—Ramipril—type 2 diabetes mellitus	8e-05	0.000835	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	7.98e-05	0.000833	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	7.95e-05	0.00083	CcSEcCtD
Canagliflozin—Fatigue—Irbesartan—type 2 diabetes mellitus	7.94e-05	0.000828	CcSEcCtD
Canagliflozin—Hypersensitivity—Valsartan—type 2 diabetes mellitus	7.89e-05	0.000824	CcSEcCtD
Canagliflozin—Convulsion—Ramipril—type 2 diabetes mellitus	7.89e-05	0.000823	CcSEcCtD
Canagliflozin—Constipation—Irbesartan—type 2 diabetes mellitus	7.87e-05	0.000822	CcSEcCtD
Canagliflozin—Hypersensitivity—Orlistat—type 2 diabetes mellitus	7.8e-05	0.000814	CcSEcCtD
Canagliflozin—Urticaria—Metformin—type 2 diabetes mellitus	7.75e-05	0.000809	CcSEcCtD
Canagliflozin—Nausea—Glyburide—type 2 diabetes mellitus	7.71e-05	0.000805	CcSEcCtD
Canagliflozin—Abdominal pain—Metformin—type 2 diabetes mellitus	7.71e-05	0.000805	CcSEcCtD
Canagliflozin—Dizziness—Gliclazide—type 2 diabetes mellitus	7.71e-05	0.000805	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	7.69e-05	0.000803	CcSEcCtD
Canagliflozin—Asthenia—Valsartan—type 2 diabetes mellitus	7.68e-05	0.000802	CcSEcCtD
Canagliflozin—Asthenia—Orlistat—type 2 diabetes mellitus	7.59e-05	0.000793	CcSEcCtD
Canagliflozin—Pruritus—Valsartan—type 2 diabetes mellitus	7.58e-05	0.000791	CcSEcCtD
Canagliflozin—Dry mouth—Ramipril—type 2 diabetes mellitus	7.58e-05	0.000791	CcSEcCtD
Canagliflozin—ABCB1—liver—type 2 diabetes mellitus	7.55e-05	0.005	CbGeAlD
Canagliflozin—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	7.53e-05	0.000786	CcSEcCtD
Canagliflozin—Pruritus—Orlistat—type 2 diabetes mellitus	7.49e-05	0.000782	CcSEcCtD
Canagliflozin—Fatigue—Losartan—type 2 diabetes mellitus	7.47e-05	0.00078	CcSEcCtD
Canagliflozin—Constipation—Losartan—type 2 diabetes mellitus	7.41e-05	0.000773	CcSEcCtD
Canagliflozin—Rash—Gliclazide—type 2 diabetes mellitus	7.35e-05	0.000767	CcSEcCtD
Canagliflozin—Dermatitis—Gliclazide—type 2 diabetes mellitus	7.34e-05	0.000767	CcSEcCtD
Canagliflozin—Urticaria—Irbesartan—type 2 diabetes mellitus	7.31e-05	0.000763	CcSEcCtD
Canagliflozin—Shock—Ramipril—type 2 diabetes mellitus	7.31e-05	0.000763	CcSEcCtD
Canagliflozin—Nervous system disorder—Ramipril—type 2 diabetes mellitus	7.28e-05	0.00076	CcSEcCtD
Canagliflozin—Abdominal pain—Irbesartan—type 2 diabetes mellitus	7.28e-05	0.00076	CcSEcCtD
Canagliflozin—Skin disorder—Ramipril—type 2 diabetes mellitus	7.21e-05	0.000753	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	7.08e-05	0.000739	CcSEcCtD
Canagliflozin—Dizziness—Valsartan—type 2 diabetes mellitus	7.08e-05	0.000739	CcSEcCtD
Canagliflozin—Dizziness—Orlistat—type 2 diabetes mellitus	7e-05	0.000731	CcSEcCtD
Canagliflozin—Asthenia—Metformin—type 2 diabetes mellitus	7e-05	0.000731	CcSEcCtD
Canagliflozin—Hypotension—Ramipril—type 2 diabetes mellitus	6.94e-05	0.000725	CcSEcCtD
Canagliflozin—Nausea—Gliclazide—type 2 diabetes mellitus	6.92e-05	0.000723	CcSEcCtD
Canagliflozin—Pruritus—Metformin—type 2 diabetes mellitus	6.9e-05	0.00072	CcSEcCtD
Canagliflozin—Urticaria—Losartan—type 2 diabetes mellitus	6.88e-05	0.000718	CcSEcCtD
Canagliflozin—Abdominal pain—Losartan—type 2 diabetes mellitus	6.85e-05	0.000715	CcSEcCtD
Canagliflozin—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	6.78e-05	0.000708	CcSEcCtD
Canagliflozin—Rash—Valsartan—type 2 diabetes mellitus	6.75e-05	0.000705	CcSEcCtD
Canagliflozin—Dermatitis—Valsartan—type 2 diabetes mellitus	6.75e-05	0.000704	CcSEcCtD
Canagliflozin—Rash—Orlistat—type 2 diabetes mellitus	6.67e-05	0.000697	CcSEcCtD
Canagliflozin—Dermatitis—Orlistat—type 2 diabetes mellitus	6.67e-05	0.000696	CcSEcCtD
Canagliflozin—Asthenia—Irbesartan—type 2 diabetes mellitus	6.6e-05	0.000689	CcSEcCtD
Canagliflozin—Pruritus—Irbesartan—type 2 diabetes mellitus	6.51e-05	0.00068	CcSEcCtD
Canagliflozin—Dizziness—Metformin—type 2 diabetes mellitus	6.45e-05	0.000673	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	6.41e-05	0.000669	CcSEcCtD
Canagliflozin—Fatigue—Ramipril—type 2 diabetes mellitus	6.4e-05	0.000669	CcSEcCtD
Canagliflozin—Hypersensitivity—Losartan—type 2 diabetes mellitus	6.38e-05	0.000666	CcSEcCtD
Canagliflozin—Nausea—Valsartan—type 2 diabetes mellitus	6.36e-05	0.000664	CcSEcCtD
Canagliflozin—Constipation—Ramipril—type 2 diabetes mellitus	6.35e-05	0.000663	CcSEcCtD
Canagliflozin—Nausea—Orlistat—type 2 diabetes mellitus	6.29e-05	0.000656	CcSEcCtD
Canagliflozin—Asthenia—Losartan—type 2 diabetes mellitus	6.22e-05	0.000649	CcSEcCtD
Canagliflozin—Rash—Metformin—type 2 diabetes mellitus	6.15e-05	0.000642	CcSEcCtD
Canagliflozin—Dermatitis—Metformin—type 2 diabetes mellitus	6.14e-05	0.000641	CcSEcCtD
Canagliflozin—Pruritus—Losartan—type 2 diabetes mellitus	6.13e-05	0.00064	CcSEcCtD
Canagliflozin—Dizziness—Irbesartan—type 2 diabetes mellitus	6.09e-05	0.000635	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	6.07e-05	0.000634	CcSEcCtD
Canagliflozin—Urticaria—Ramipril—type 2 diabetes mellitus	5.9e-05	0.000616	CcSEcCtD
Canagliflozin—Abdominal pain—Ramipril—type 2 diabetes mellitus	5.87e-05	0.000613	CcSEcCtD
Canagliflozin—Rash—Irbesartan—type 2 diabetes mellitus	5.8e-05	0.000606	CcSEcCtD
Canagliflozin—Dermatitis—Irbesartan—type 2 diabetes mellitus	5.8e-05	0.000605	CcSEcCtD
Canagliflozin—Nausea—Metformin—type 2 diabetes mellitus	5.79e-05	0.000605	CcSEcCtD
Canagliflozin—Dizziness—Losartan—type 2 diabetes mellitus	5.73e-05	0.000598	CcSEcCtD
Canagliflozin—Hypersensitivity—Ramipril—type 2 diabetes mellitus	5.47e-05	0.000571	CcSEcCtD
Canagliflozin—Nausea—Irbesartan—type 2 diabetes mellitus	5.47e-05	0.000571	CcSEcCtD
Canagliflozin—Rash—Losartan—type 2 diabetes mellitus	5.46e-05	0.00057	CcSEcCtD
Canagliflozin—Dermatitis—Losartan—type 2 diabetes mellitus	5.46e-05	0.00057	CcSEcCtD
Canagliflozin—Asthenia—Ramipril—type 2 diabetes mellitus	5.33e-05	0.000556	CcSEcCtD
Canagliflozin—Pruritus—Ramipril—type 2 diabetes mellitus	5.26e-05	0.000549	CcSEcCtD
Canagliflozin—Nausea—Losartan—type 2 diabetes mellitus	5.15e-05	0.000537	CcSEcCtD
Canagliflozin—Dizziness—Ramipril—type 2 diabetes mellitus	4.91e-05	0.000513	CcSEcCtD
Canagliflozin—Rash—Ramipril—type 2 diabetes mellitus	4.68e-05	0.000489	CcSEcCtD
Canagliflozin—Dermatitis—Ramipril—type 2 diabetes mellitus	4.68e-05	0.000488	CcSEcCtD
Canagliflozin—Nausea—Ramipril—type 2 diabetes mellitus	4.41e-05	0.000461	CcSEcCtD
Canagliflozin—ABCB1—Metabolism—UCP2—type 2 diabetes mellitus	4.59e-06	5.29e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—HSD11B1—type 2 diabetes mellitus	4.59e-06	5.29e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—UCP3—type 2 diabetes mellitus	4.59e-06	5.29e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GNB3—type 2 diabetes mellitus	4.53e-06	5.22e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PPARGC1A—type 2 diabetes mellitus	4.53e-06	5.22e-05	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—ADCY5—type 2 diabetes mellitus	4.51e-06	5.2e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—HMOX1—type 2 diabetes mellitus	4.5e-06	5.19e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—CALM1—type 2 diabetes mellitus	4.48e-06	5.16e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—HSD3B2—type 2 diabetes mellitus	4.45e-06	5.13e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—LPA—type 2 diabetes mellitus	4.45e-06	5.13e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GCKR—type 2 diabetes mellitus	4.45e-06	5.13e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—KCNJ11—type 2 diabetes mellitus	4.45e-06	5.13e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CAT—type 2 diabetes mellitus	4.44e-06	5.12e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—GNB3—type 2 diabetes mellitus	4.43e-06	5.11e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—HMOX1—type 2 diabetes mellitus	4.41e-06	5.09e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—APOA1—type 2 diabetes mellitus	4.41e-06	5.08e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CDO1—type 2 diabetes mellitus	4.38e-06	5.05e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GPD2—type 2 diabetes mellitus	4.38e-06	5.05e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—AVP—type 2 diabetes mellitus	4.37e-06	5.04e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—APOB—type 2 diabetes mellitus	4.31e-06	4.97e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PCK1—type 2 diabetes mellitus	4.31e-06	4.97e-05	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—TGFB1—type 2 diabetes mellitus	4.29e-06	4.94e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PPARA—type 2 diabetes mellitus	4.28e-06	4.93e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ALDOB—type 2 diabetes mellitus	4.27e-06	4.92e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—APOB—type 2 diabetes mellitus	4.23e-06	4.87e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—type 2 diabetes mellitus	4.22e-06	4.87e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PRKCB—type 2 diabetes mellitus	4.21e-06	4.85e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GSTM1—type 2 diabetes mellitus	4.2e-06	4.84e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—AK1—type 2 diabetes mellitus	4.18e-06	4.82e-05	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—AKT1—type 2 diabetes mellitus	4.16e-06	4.8e-05	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—AKT1—type 2 diabetes mellitus	4.16e-06	4.8e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—NOS2—type 2 diabetes mellitus	4.16e-06	4.79e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—AGT—type 2 diabetes mellitus	4.14e-06	4.78e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—type 2 diabetes mellitus	4.14e-06	4.77e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—LPL—type 2 diabetes mellitus	4.12e-06	4.75e-05	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—PPARA—type 2 diabetes mellitus	4.07e-06	4.69e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—APOE—type 2 diabetes mellitus	4.06e-06	4.68e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—HK1—type 2 diabetes mellitus	4.04e-06	4.65e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ADCY5—type 2 diabetes mellitus	4.03e-06	4.65e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GPX1—type 2 diabetes mellitus	4.02e-06	4.63e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—APOA1—type 2 diabetes mellitus	4.01e-06	4.63e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GLP1R—type 2 diabetes mellitus	3.97e-06	4.57e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—ADCY5—type 2 diabetes mellitus	3.95e-06	4.55e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—type 2 diabetes mellitus	3.94e-06	4.54e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CD36—type 2 diabetes mellitus	3.91e-06	4.51e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—LPA—type 2 diabetes mellitus	3.9e-06	4.5e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—HSD3B2—type 2 diabetes mellitus	3.9e-06	4.5e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—KCNJ11—type 2 diabetes mellitus	3.9e-06	4.5e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GCKR—type 2 diabetes mellitus	3.9e-06	4.5e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PPP2CA—type 2 diabetes mellitus	3.87e-06	4.46e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SLC5A4—type 2 diabetes mellitus	3.86e-06	4.45e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—MAT1A—type 2 diabetes mellitus	3.86e-06	4.45e-05	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—APOA1—type 2 diabetes mellitus	3.82e-06	4.4e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ALDOB—type 2 diabetes mellitus	3.74e-06	4.31e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—HBA2—type 2 diabetes mellitus	3.73e-06	4.3e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—G6PC—type 2 diabetes mellitus	3.73e-06	4.3e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PPP1R3C—type 2 diabetes mellitus	3.73e-06	4.3e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ENPP1—type 2 diabetes mellitus	3.73e-06	4.3e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ND1—type 2 diabetes mellitus	3.73e-06	4.3e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—MTHFR—type 2 diabetes mellitus	3.71e-06	4.28e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—SLC2A2—type 2 diabetes mellitus	3.7e-06	4.27e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IGF1—type 2 diabetes mellitus	3.69e-06	4.25e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—AKT2—type 2 diabetes mellitus	3.68e-06	4.25e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PPARA—type 2 diabetes mellitus	3.64e-06	4.2e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CPT1A—type 2 diabetes mellitus	3.63e-06	4.18e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—MTR—type 2 diabetes mellitus	3.63e-06	4.18e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GCGR—type 2 diabetes mellitus	3.61e-06	4.16e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—PPARA—type 2 diabetes mellitus	3.56e-06	4.11e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—NAMPT—type 2 diabetes mellitus	3.56e-06	4.1e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PPARG—type 2 diabetes mellitus	3.54e-06	4.08e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—HBA1—type 2 diabetes mellitus	3.53e-06	4.08e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—LIPC—type 2 diabetes mellitus	3.53e-06	4.08e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GCK—type 2 diabetes mellitus	3.53e-06	4.08e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—AGT—type 2 diabetes mellitus	3.52e-06	4.06e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYP11A1—type 2 diabetes mellitus	3.51e-06	4.05e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—SERPINE1—type 2 diabetes mellitus	3.5e-06	4.03e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GLP1R—type 2 diabetes mellitus	3.47e-06	4.01e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CALM1—type 2 diabetes mellitus	3.47e-06	4e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—APOE—type 2 diabetes mellitus	3.45e-06	3.98e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—SLC9A1—type 2 diabetes mellitus	3.45e-06	3.98e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—APOA1—type 2 diabetes mellitus	3.41e-06	3.94e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CETP—type 2 diabetes mellitus	3.41e-06	3.93e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYTB—type 2 diabetes mellitus	3.41e-06	3.93e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—OXCT1—type 2 diabetes mellitus	3.41e-06	3.93e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—APOA1—type 2 diabetes mellitus	3.34e-06	3.86e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PIK3R1—type 2 diabetes mellitus	3.34e-06	3.85e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—NOS3—type 2 diabetes mellitus	3.34e-06	3.85e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SRD5A1—type 2 diabetes mellitus	3.32e-06	3.83e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—SLC2A2—type 2 diabetes mellitus	3.24e-06	3.74e-05	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—AKT1—type 2 diabetes mellitus	3.21e-06	3.7e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CPT1A—type 2 diabetes mellitus	3.18e-06	3.66e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—MTR—type 2 diabetes mellitus	3.18e-06	3.66e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—SREBF1—type 2 diabetes mellitus	3.17e-06	3.66e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—SNAP25—type 2 diabetes mellitus	3.17e-06	3.66e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PSMD6—type 2 diabetes mellitus	3.17e-06	3.66e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ACACA—type 2 diabetes mellitus	3.17e-06	3.65e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—STAR—type 2 diabetes mellitus	3.17e-06	3.65e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—HSD17B3—type 2 diabetes mellitus	3.17e-06	3.65e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—NAMPT—type 2 diabetes mellitus	3.12e-06	3.59e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CTGF—type 2 diabetes mellitus	3.11e-06	3.59e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—HBA1—type 2 diabetes mellitus	3.1e-06	3.57e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—LIPC—type 2 diabetes mellitus	3.1e-06	3.57e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GCK—type 2 diabetes mellitus	3.1e-06	3.57e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—HMGCR—type 2 diabetes mellitus	3.08e-06	3.56e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYP11A1—type 2 diabetes mellitus	3.08e-06	3.55e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PIK3R1—type 2 diabetes mellitus	3.04e-06	3.51e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CBS—type 2 diabetes mellitus	3.04e-06	3.5e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ABCC8—type 2 diabetes mellitus	3.04e-06	3.5e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—SLC9A1—type 2 diabetes mellitus	3.02e-06	3.49e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ADRA2A—type 2 diabetes mellitus	3.02e-06	3.48e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PPARG—type 2 diabetes mellitus	3.01e-06	3.47e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CETP—type 2 diabetes mellitus	2.99e-06	3.45e-05	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—AKT1—type 2 diabetes mellitus	2.98e-06	3.44e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—INS—type 2 diabetes mellitus	2.95e-06	3.4e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—type 2 diabetes mellitus	2.93e-06	3.38e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—COX2—type 2 diabetes mellitus	2.92e-06	3.37e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SLC5A2—type 2 diabetes mellitus	2.92e-06	3.37e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYP2E1—type 2 diabetes mellitus	2.9e-06	3.34e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NCOA6—type 2 diabetes mellitus	2.87e-06	3.31e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYP1A2—type 2 diabetes mellitus	2.87e-06	3.31e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—SLC2A1—type 2 diabetes mellitus	2.87e-06	3.31e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—UCP2—type 2 diabetes mellitus	2.82e-06	3.26e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—HSD11B1—type 2 diabetes mellitus	2.82e-06	3.26e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—UCP3—type 2 diabetes mellitus	2.82e-06	3.26e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYP3A4—type 2 diabetes mellitus	2.8e-06	3.22e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	2.78e-06	3.21e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—SREBF1—type 2 diabetes mellitus	2.78e-06	3.2e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PSMD6—type 2 diabetes mellitus	2.78e-06	3.2e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—SNAP25—type 2 diabetes mellitus	2.78e-06	3.2e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GCG—type 2 diabetes mellitus	2.75e-06	3.17e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—SLC2A4—type 2 diabetes mellitus	2.75e-06	3.17e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CTGF—type 2 diabetes mellitus	2.73e-06	3.14e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ALB—type 2 diabetes mellitus	2.7e-06	3.12e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—HMGCR—type 2 diabetes mellitus	2.7e-06	3.12e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PCK1—type 2 diabetes mellitus	2.66e-06	3.06e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—ALB—type 2 diabetes mellitus	2.65e-06	3.05e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ADRA2A—type 2 diabetes mellitus	2.64e-06	3.05e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PIK3R1—type 2 diabetes mellitus	2.59e-06	2.98e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—NOS3—type 2 diabetes mellitus	2.59e-06	2.98e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYP2E1—type 2 diabetes mellitus	2.54e-06	2.93e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—SLC2A1—type 2 diabetes mellitus	2.51e-06	2.9e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYP1A2—type 2 diabetes mellitus	2.51e-06	2.9e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—HK1—type 2 diabetes mellitus	2.49e-06	2.87e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—SRC—type 2 diabetes mellitus	2.47e-06	2.85e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYP3A4—type 2 diabetes mellitus	2.45e-06	2.82e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GCG—type 2 diabetes mellitus	2.41e-06	2.78e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—SLC2A4—type 2 diabetes mellitus	2.41e-06	2.78e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—VEGFA—type 2 diabetes mellitus	2.41e-06	2.78e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GCKR—type 2 diabetes mellitus	2.4e-06	2.77e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—KCNJ11—type 2 diabetes mellitus	2.4e-06	2.77e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—HSD3B2—type 2 diabetes mellitus	2.4e-06	2.77e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—LPA—type 2 diabetes mellitus	2.4e-06	2.77e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PPARGC1A—type 2 diabetes mellitus	2.37e-06	2.73e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GNB3—type 2 diabetes mellitus	2.37e-06	2.73e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PTGS2—type 2 diabetes mellitus	2.37e-06	2.73e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—HMOX1—type 2 diabetes mellitus	2.36e-06	2.72e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CAT—type 2 diabetes mellitus	2.33e-06	2.68e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ALDOB—type 2 diabetes mellitus	2.3e-06	2.66e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—APOB—type 2 diabetes mellitus	2.26e-06	2.6e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—TGFB1—type 2 diabetes mellitus	2.21e-06	2.55e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTM1—type 2 diabetes mellitus	2.2e-06	2.53e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—LPL—type 2 diabetes mellitus	2.16e-06	2.49e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	2.14e-06	2.47e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ADCY5—type 2 diabetes mellitus	2.11e-06	2.43e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GPX1—type 2 diabetes mellitus	2.1e-06	2.43e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GNB3—type 2 diabetes mellitus	2.08e-06	2.39e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PPARGC1A—type 2 diabetes mellitus	2.08e-06	2.39e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—HMOX1—type 2 diabetes mellitus	2.07e-06	2.38e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CD36—type 2 diabetes mellitus	2.05e-06	2.36e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CAT—type 2 diabetes mellitus	2.04e-06	2.35e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PPP2CA—type 2 diabetes mellitus	2.02e-06	2.33e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	2e-06	2.3e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—APOB—type 2 diabetes mellitus	1.98e-06	2.28e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	1.96e-06	2.26e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	1.96e-06	2.26e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—MTHFR—type 2 diabetes mellitus	1.94e-06	2.24e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTM1—type 2 diabetes mellitus	1.93e-06	2.22e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	1.92e-06	2.21e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	1.91e-06	2.2e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	1.91e-06	2.2e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	1.91e-06	2.2e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PPARA—type 2 diabetes mellitus	1.91e-06	2.2e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	1.9e-06	2.19e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—LPL—type 2 diabetes mellitus	1.89e-06	2.18e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	1.86e-06	2.15e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ADCY5—type 2 diabetes mellitus	1.85e-06	2.13e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—AGT—type 2 diabetes mellitus	1.85e-06	2.13e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GPX1—type 2 diabetes mellitus	1.84e-06	2.13e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	1.84e-06	2.12e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CALM1—type 2 diabetes mellitus	1.81e-06	2.09e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—APOE—type 2 diabetes mellitus	1.81e-06	2.08e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CD36—type 2 diabetes mellitus	1.8e-06	2.07e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—APOA1—type 2 diabetes mellitus	1.79e-06	2.06e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PPP2CA—type 2 diabetes mellitus	1.77e-06	2.04e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	1.71e-06	1.97e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	1.71e-06	1.97e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	1.71e-06	1.97e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—MTHFR—type 2 diabetes mellitus	1.7e-06	1.96e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	1.68e-06	1.94e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PPARA—type 2 diabetes mellitus	1.67e-06	1.92e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	1.66e-06	1.92e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	1.63e-06	1.88e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—AGT—type 2 diabetes mellitus	1.62e-06	1.86e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CALM1—type 2 diabetes mellitus	1.59e-06	1.83e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—APOE—type 2 diabetes mellitus	1.58e-06	1.83e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PPARG—type 2 diabetes mellitus	1.57e-06	1.82e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—APOA1—type 2 diabetes mellitus	1.57e-06	1.81e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	1.57e-06	1.8e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	1.55e-06	1.78e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	1.55e-06	1.78e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—INS—type 2 diabetes mellitus	1.54e-06	1.78e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—AKT1—type 2 diabetes mellitus	1.54e-06	1.77e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	1.48e-06	1.71e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	1.48e-06	1.71e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PPARG—type 2 diabetes mellitus	1.38e-06	1.59e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PIK3R1—type 2 diabetes mellitus	1.35e-06	1.56e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—NOS3—type 2 diabetes mellitus	1.35e-06	1.56e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—INS—type 2 diabetes mellitus	1.35e-06	1.56e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	1.28e-06	1.47e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.28e-06	1.47e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	1.27e-06	1.47e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	1.26e-06	1.45e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ALB—type 2 diabetes mellitus	1.24e-06	1.43e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PTGS2—type 2 diabetes mellitus	1.24e-06	1.43e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	1.22e-06	1.41e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—AKT1—type 2 diabetes mellitus	1.19e-06	1.37e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PIK3R1—type 2 diabetes mellitus	1.19e-06	1.37e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—NOS3—type 2 diabetes mellitus	1.19e-06	1.37e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	1.19e-06	1.37e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	1.16e-06	1.34e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	1.14e-06	1.31e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	1.14e-06	1.31e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	1.11e-06	1.28e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	1.09e-06	1.26e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PTGS2—type 2 diabetes mellitus	1.09e-06	1.25e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	1.05e-06	1.21e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	1.03e-06	1.19e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	9.96e-07	1.15e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	9.8e-07	1.13e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	9.76e-07	1.13e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	9.65e-07	1.11e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	8.5e-07	9.8e-06	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	8.34e-07	9.61e-06	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	7.64e-07	8.81e-06	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	7.31e-07	8.43e-06	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	7.31e-07	8.43e-06	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	6.69e-07	7.71e-06	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—AKT1—type 2 diabetes mellitus	6.23e-07	7.18e-06	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—AKT1—type 2 diabetes mellitus	5.46e-07	6.29e-06	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	3.36e-07	3.88e-06	CbGpPWpGaD
